Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company™s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell™s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor™s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company™s founding intellectual property is based on the groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead Institute for Biomedical Research. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/19/14 | $23,500,000 | Series A |
Atlas Venture Johnson & Johnson Innovation Polaris Partners SR One The Longevity Fund | undisclosed |
| 12/18/15 | $33,000,000 | Series B |
Atlas Venture Brace Pharma Johnson & Johnson Development Corporation (JJDC) Polaris Partners Remeditex Ventures Sanofi-Genzyme BioVentures SR One | undisclosed |
